Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Technology for effective absorption of drugs into blood

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TORU20210730001
Publicado:
27/08/2021
Caducidad:
28/08/2022
Resumen:
A Russian company is engaged in the development of advanced technologies in the medical field. The organization develops new technology for the system of oral administration of medicines into the blood. The system is designed to be used in combination with medications that otherwise have low oral bioavailability. The company is looking for new partners from the medical field to conclude the commercial agreement with technical assistance or research cooperation agreements.

Details

Tittle:
Technology for effective absorption of drugs into blood
Summary:
A Russian company is engaged in the development of advanced technologies in the medical field. The organization develops new technology for the system of oral administration of medicines into the blood. The system is designed to be used in combination with medications that otherwise have low oral bioavailability. The company is looking for new partners from the medical field to conclude the commercial agreement with technical assistance or research cooperation agreements.
Description:
The Russian company is a developer of innovative technology. It was founded in 1916 and over the years of its existence annually extol the contribution to innovation and development of the medical field.
There are a number of drugs with extremely low oral bioavailability. The only insignificant portion of a drug reaches the bloodstream when administrated orally. This requires more complex ways of taking the medicine: subcutaneous and intravenous injections. The basis of the developed technology is a unique multi-component oral administration system of drugs into the blood. The chemical composition based on modified chitosan is a nanostructured multi-layered matrix that implements transport and protective functions simultaneously. The composition in gel form inhibits the destruction of the medicine it transfers under the influence of proteolytic enzymes of the gastrointestinal tract while absorbing into the blood where it gradually decomposes and releases the drug without damaging the liver.
The chemical composition (the drug transport matrix) has been developed at the present moment. The structure obtained has been studied and the possibility of transferring various drugs has been determined. The primary tests on the bioavailability of insulin were carried out. Based on the results of preliminary tests of the new drug on small lab animals, the bioavailability of insulin with oral administration of the new drug is 20-25%.
First of all, an independent test on the bioavailability of the transferred medicines (on large lab animals in particular) and development of the reproducibility of substances are necessary for the further development of the project, after which it is possible to conduct preclinical trials of the drug.
The Russian organization is looking for new foreign partners from the medical field (pharmacological companies, medical research centers) to conclude a mutually beneficial commercial agreement with technical assistance or research cooperation agreements. Under the commercial agreement with technical assistance, the developers consider the sale of rights on technology, as there are no sufficient capacities at their disposal to do further research and for develop the product to its final form.
As a result of the research cooperation agreement, developers consider joint research and development. In this case, developers take on the task of developing the technology of the required drug. The tasks of conducting bioavailability tests by GMP standards and further preclinical trials remain for the partners.
Advantages and Innovations:
The developed system allows partial or complete replacement of injections with an oral pill, which is more convenient and not painful way to administer a drug. The unique chitosan-based multilayered complex protects the carried drug from the destructive effect of the acidic environment of the gastric tract and allows it to stick to and penetrate through intestinal walls. The bioavailability of the drug reaches 20% even without the use of capsules that protect against gastric acids.
One of the innovations is the alternation of drug-containing layers and protective layers around the core in the matrix. Innovations concerning the core of the matrix, which allows a complex to be absorbed in the intestine, are currently know-how secrets and cannot be disclosed. The technology of production has the ability to control the release time of carried drugs, giving the opportunity for the individual approach to treatment.
Stage of Development:
Proposal under development
IPs:
Secret Know-how

Partner sought

Type and Role of Partner Sought:
Type: SMEs, large companies, pharmaceutical companies, medical research centers
Role: Pharmaceutical companies are sought for buying of technology rights under the commercial agreement with technical assistance.
Joint research and development with pharmaceutical companies and research centers are considered as well, need the independent tests under EU standards.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Russian

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos